5-Amino-1MQ
An NNMT inhibitor studied for increasing cellular metabolism, reducing fat mass, and preserving muscle during weight loss research.
VK2735 is a GLP-1/GIP dual receptor agonist developed for the treatment of obesity. It is under research for its significant potential in weight loss and metabolic improvement.
In the literature, VK2735 appears most often in work focused on weight loss, fat loss and metabolism. Studies in this area tend to look at mechanisms and observed effects in laboratory and preclinical settings rather than outcomes in people, so the picture is best read as a map of where researchers have been curious — not as evidence of any benefit.
VK2735 is catalogued here under powder peptides. Coverage of this compound varies in quality and depth, and much of it remains early-stage. Reading the underlying research directly is the only way to judge how strong any particular finding is.
Tap a topic to see which peptides are most studied for it.
An NNMT inhibitor studied for increasing cellular metabolism, reducing fat mass, and preserving muscle during weight loss research.
A modified fragment of human growth hormone studied specifically for fat metabolism without affecting blood sugar or growth.
A lipotropic blend with B12 studied for fat metabolism and energy support.
Research use only. This page summarizes areas of published study and is not medical advice. No dosing, protocol, or usage guidance is provided.